# Cajal Therapeutics

> Cajal Therapeutics (originally launched as Cajal Neuroscience) is a Seattle biotechnology company developing novel medicines to restore biological homeostasis, with a focus on neurodegenerative diseases, anemias of inflammation, and iron-related disorders. Built on a platform that pairs integrative human genetics, high-throughput functional genomics, and industrialized whole-brain imaging with deep neuroscience expertise, the company aims to systematically validate disease targets at unprecedented scale and translate them into small molecule and RNA therapeutics. It launched in November 2022 with a $96 million Series A and counts a roster of celebrated neuroscientists among its co-founders.

- **Founded:** 2020
- **Headquarters:** Seattle, Washington, United States
- **Founders:** Andrew Dervan (Co-Founder & Co-CEO), Ian Peikon (Co-Founder & Co-CEO), Rob Hershberg (Co-Founder & Executive Chairman), Josh Wolfe (Co-Founder & Lux Capital Managing Partner), Huda Zoghbi (Co-Founder & Scientific Advisory Board Chair), Anthony Zador (Co-Founder & Scientific Advisor), Charles Zuker (Co-Founder & Scientific Advisor)
- **Team size:** ~38 employees
- **Products:** Target & Drug Discovery Platform, CTX001, Small molecule & RNA medicines
- **Notable:** Launched in November 2022 with a $96 million Series A, one of the larger neuroscience launches of the year., Assembled a co-founding scientific team including renowned neuroscientists Huda Zoghbi, Anthony Zador, and Charles Zuker., Built an integrated platform spanning human genetics, multi-omics, functional genomics, and industrialized whole-brain imaging.

## Products & services

- **Target & Drug Discovery Platform** — An integrated platform combining human genetics and multi-omics, highly multiplexed functional genomics, and industrialized whole-brain imaging to systematically validate the thousands of targets implicated in diseases like Alzheimer's and Parkinson's.
- **CTX001** — Lead program described as a first-in-class iron mobilizer intended to restore iron transport and improve iron availability for key metabolic and cellular processes.
- **Small molecule & RNA medicines** — Therapeutic programs designed to restore iron homeostasis across systemic and neurologic conditions.

## Achievements

- Launched in November 2022 with a $96 million Series A, one of the larger neuroscience launches of the year.
- Assembled a co-founding scientific team including renowned neuroscientists Huda Zoghbi, Anthony Zador, and Charles Zuker.
- Built an integrated platform spanning human genetics, multi-omics, functional genomics, and industrialized whole-brain imaging.
- Attracted Bristol Myers Squibb and Evotec as strategic investors alongside Lux Capital and The Column Group.
- Evolved its focus toward iron homeostasis with lead program CTX001, a first-in-class iron mobilizer.

## Latest updates

- **2022-11** — Cajal Neuroscience launches publicly with $96M Series A to transform target and drug discovery in neurodegeneration.
- **2024-01** — Company operating under the Cajal Therapeutics brand (cajal-tx.com), broadening focus to homeostasis with iron-mobilizer lead program CTX001.

## Links

- Website: https://cajal-tx.com
- LinkedIn: http://www.linkedin.com/company/cajal-tx
- Twitter/X: https://twitter.com/cajalneuro

---

Profile page: https://yespress.io/cajal-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-15